{"title":"关于锂处方和监测的初级和中级医疗联合研究","authors":"Seema Vekaria, Chetan Shah, Tim Gale, Cathy Geeson, Maxine Davis, Janet Weir, Promilla Singh","doi":"10.1002/pnp.823","DOIUrl":null,"url":null,"abstract":"Lithium is licensed for the treatment and prophylaxis of mania, bipolar disorder, recurrent depression and intentional self‐harming behaviour. Despite its effectiveness, lithium use is complicated by its narrow therapeutic range. In 2009, the National Patient Safety Agency issued a safety alert highlighting the issues and requested NHS organisations ensure reliable systems and monitoring were in place. This article explores how well the guidelines are followed in terms of lithium prescribing and monitoring across primary and secondary care.","PeriodicalId":43913,"journal":{"name":"Progress in Neurology and Psychiatry","volume":null,"pages":null},"PeriodicalIF":1.3000,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Joint primary and secondary care study of lithium prescribing and monitoring\",\"authors\":\"Seema Vekaria, Chetan Shah, Tim Gale, Cathy Geeson, Maxine Davis, Janet Weir, Promilla Singh\",\"doi\":\"10.1002/pnp.823\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Lithium is licensed for the treatment and prophylaxis of mania, bipolar disorder, recurrent depression and intentional self‐harming behaviour. Despite its effectiveness, lithium use is complicated by its narrow therapeutic range. In 2009, the National Patient Safety Agency issued a safety alert highlighting the issues and requested NHS organisations ensure reliable systems and monitoring were in place. This article explores how well the guidelines are followed in terms of lithium prescribing and monitoring across primary and secondary care.\",\"PeriodicalId\":43913,\"journal\":{\"name\":\"Progress in Neurology and Psychiatry\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":1.3000,\"publicationDate\":\"2024-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Progress in Neurology and Psychiatry\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1002/pnp.823\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"NEUROSCIENCES\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Progress in Neurology and Psychiatry","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1002/pnp.823","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"NEUROSCIENCES","Score":null,"Total":0}
Joint primary and secondary care study of lithium prescribing and monitoring
Lithium is licensed for the treatment and prophylaxis of mania, bipolar disorder, recurrent depression and intentional self‐harming behaviour. Despite its effectiveness, lithium use is complicated by its narrow therapeutic range. In 2009, the National Patient Safety Agency issued a safety alert highlighting the issues and requested NHS organisations ensure reliable systems and monitoring were in place. This article explores how well the guidelines are followed in terms of lithium prescribing and monitoring across primary and secondary care.
期刊介绍：
Progress in Neurology and Psychiatry is published nine times a year, and is a journal for specialists in secondary care, GPs with an interest in neurology and psychiatry, community psychiatric nurses and other specialist healthcare professionals. Articles cover management, news updates and opinion in all areas of neurology and psychiatry.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
